Last reviewed · How we verify
Palm Oil capsule
Palm Oil capsule, marketed by RDC Clinical Pty Ltd, holds a unique position in its therapeutic segment despite limited public revenue data. A key strength lies in its composition patent, which is protected until 2028, providing a significant barrier to generic competition. The primary risk is the lack of detailed clinical trial results and primary indication data, which may limit its market expansion and adoption by healthcare providers.
At a glance
| Generic name | Palm Oil capsule |
|---|---|
| Sponsor | RDC Clinical Pty Ltd |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Role of Omega-DEK in Childhood Apraxia of Speech (PHASE2)
- Efficacy and Safety of Tocotrienols in CADASIL (PHASE2)
- A Clinical Trial to Examine Lysoveta on Cognitive Function in Healthy Adults With Self-perceived Memory Problems (NA)
- B-vitamins and Omega-3 Fatty Acids and Biomarkers of Brain Atrophy. (NA)
- Optimizing CNS DHA Delivery in Elderly Adults at Risk for Dementia (NA)
- Changes in Muscle Strength, Inflammatory Markers, and Body Composition in Response to Alternate Day Fasting Combined With Krill Oil Supplementation in Adults With Overweight and Obesity (NA)
- Comparison of 2 Extracts of Saw Palmetto Versus Placebo on Lower Urinary Tract Symptoms (LUTS) and Urinary Frequency (PHASE4)
- Investigation of Krill Oil in Women with Premenstrual Syndrome (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Palm Oil capsule CI brief — competitive landscape report
- Palm Oil capsule updates RSS · CI watch RSS
- RDC Clinical Pty Ltd portfolio CI